CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
06 05 2019
Historique:
received: 12 02 2017
revised: 08 11 2018
accepted: 01 03 2019
pubmed: 27 3 2019
medline: 6 5 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

Chemokines have crucial roles in organ development and orchestration of leukocyte migration. The chemokine CCL22 is expressed constitutively at high levels in the lymph node, but the functional significance of this expression is so far unknown. Studying a newly established CCL22-deficient mouse, we demonstrate that CCL22 expression by dendritic cells (DCs) promotes the formation of cell-cell contacts and interaction with regulatory T cells (T reg) through their CCR4 receptor. Vaccination of CCL22-deficient mice led to excessive T cell responses that were also observed when wild-type mice were vaccinated using CCL22-deficient DCs. Tumor-bearing mice with CCL22 deficiency showed prolonged survival upon vaccination, and further, CCL22-deficient mice had increased susceptibility to inflammatory disease. In conclusion, we identify the CCL22-CCR4 axis as an immune checkpoint that is crucial for the control of T cell immunity.

Identifiants

pubmed: 30910796
pii: jem.20170277
doi: 10.1084/jem.20170277
pmc: PMC6504218
doi:

Substances chimiques

Ccl22 protein, mouse 0
Chemokine CCL22 0
Receptors, CCR4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1170-1181

Informations de copyright

© 2019 Rapp et al.

Références

Science. 1999 Apr 30;284(5415):819-22
pubmed: 10221917
Nature. 1999 Aug 19;400(6746):776-80
pubmed: 10466728
Cell. 1999 Oct 1;99(1):23-33
pubmed: 10520991
Eur J Immunol. 2000 Apr;30(4):1030-9
pubmed: 10760790
J Leukoc Biol. 2000 Sep;68(3):400-4
pubmed: 10985257
Eur J Immunol. 2001 Mar;31(3):812-22
pubmed: 11241286
J Exp Med. 2001 Sep 17;194(6):847-53
pubmed: 11560999
J Immunol. 2001 Nov 1;167(9):4791-5
pubmed: 11673480
Mol Immunol. 2002 May;38(12-13):881-5
pubmed: 12009564
J Immunol. 2002 Sep 1;169(5):2303-12
pubmed: 12193695
J Exp Med. 2003 Mar 3;197(5):585-99
pubmed: 12615900
Nature. 2004 Jan 8;427(6970):154-9
pubmed: 14712275
Annu Rev Immunol. 2004;22:891-928
pubmed: 15032599
J Immunol. 2004 Apr 15;172(8):4676-80
pubmed: 15067041
J Exp Med. 2004 Apr 19;199(8):1113-20
pubmed: 15096537
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
J Exp Med. 2005 Apr 4;201(7):1037-44
pubmed: 15809349
Blood. 2005 Aug 15;106(4):1314-22
pubmed: 15870184
Blood. 2006 Jan 15;107(2):628-36
pubmed: 16179369
Nat Immunol. 2006 Jan;7(1):83-92
pubmed: 16311599
J Exp Med. 2006 Mar 20;203(3):505-11
pubmed: 16533880
Nat Rev Immunol. 2006 Apr;6(4):295-307
pubmed: 16557261
Nature. 2006 Apr 13;440(7086):890-5
pubmed: 16612374
Cancer Sci. 2006 Nov;97(11):1139-46
pubmed: 16952304
J Exp Med. 2007 Jan 22;204(1):57-63
pubmed: 17200412
J Immunol. 2007 Mar 15;178(6):3358-62
pubmed: 17339428
J Exp Med. 2007 Apr 16;204(4):735-45
pubmed: 17371928
J Exp Med. 2007 Jun 11;204(6):1327-34
pubmed: 17548518
J Exp Med. 2007 Jun 11;204(6):1335-47
pubmed: 17548521
Curr Opin Immunol. 2008 Apr;20(2):241-6
pubmed: 18508251
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10221-6
pubmed: 18621704
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8
pubmed: 18635688
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
Int Immunol. 2009 Oct;21(10):1105-11
pubmed: 19737784
Nat Immunol. 2011 May;12(5):391-8
pubmed: 21441933
J Clin Invest. 2011 Aug;121(8):3024-8
pubmed: 21737880
Blood. 2011 Nov 3;118(18):4853-62
pubmed: 21908423
Gastroenterology. 2012 Feb;142(2):335-45
pubmed: 22057112
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Blood. 2012 Aug 9;120(6):1237-45
pubmed: 22760781
BMC Gastroenterol. 2012 Jul 31;12:97
pubmed: 22849659
J Immunol. 2012 Oct 15;189(8):4175-81
pubmed: 22984082
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
Immunol Rev. 2014 May;259(1):40-59
pubmed: 24712458
Nat Immunol. 2014 Nov;15(11):1070-8
pubmed: 25263123
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Immunology. 2016 Jun;148(2):174-86
pubmed: 26868141
Oncoimmunology. 2015 Oct 29;5(3):e1105428
pubmed: 27195186
Lab Invest. 1993 Aug;69(2):238-49
pubmed: 8350599
J Immunol. 1997 Mar 15;158(6):2723-30
pubmed: 9058806
J Biol Chem. 1998 Jan 16;273(3):1764-8
pubmed: 9430724
J Exp Med. 1998 Aug 3;188(3):451-63
pubmed: 9687523
J Exp Med. 1999 Feb 1;189(3):451-60
pubmed: 9927507

Auteurs

Moritz Rapp (M)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Maximilian W M Wintergerst (MWM)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Wolfgang G Kunz (WG)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Viola K Vetter (VK)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Max M L Knott (MML)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Dominik Lisowski (D)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Sascha Haubner (S)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Stefan Moder (S)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Raffael Thaler (R)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Stephan Eiber (S)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Bastian Meyer (B)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Natascha Röhrle (N)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Ignazio Piseddu (I)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Simon Grassmann (S)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany.

Patrick Layritz (P)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Benjamin Kühnemuth (B)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Susanne Stutte (S)

Department of Immunology, Harvard Medical School, Boston, MA.

Carole Bourquin (C)

School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Department of Anaesthetics, Pharmacology, Intensive Care and Emergencies, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Ulrich H von Andrian (UH)

Department of Immunology, Harvard Medical School, Boston, MA uva@hms.harvard.edu.
The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston, MA.

Stefan Endres (S)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany endres@lmu.de.
German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.

David Anz (D)

Center of Integrated Protein Science Munich, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH